

**A****Overall survival**Compared with  $\geq 50\%$ : immunotherapy $\geq 50\%$ : nivolumab+ipilimumab

docetaxel

plaCT

Compared with docetaxel

&lt;1%: immunotherapy

1-49%: immunotherapy

Compared with plaCT

&lt;1%: nivolumab\_ipilimumab

&lt;1%: plaCT\_immunotherapy


&lt;1%: plaCT\_nivolumab\_ipilimumab

 $\geq 50\%$ : plaCT\_immunotherapy $\geq 50\%$ : plaCT\_nivolumab\_ipilimumab

1-49%: nivolumab\_ipilimumab

1-49%: plaCT\_immunotherapy

1-49%: plaCT\_nivolumab\_ipilimumab

**B****Progression free survival**Compared with  $\geq 50\%$ : immunotherapy $\geq 50\%$ : nivolumab\_ipilimumab

docetaxel

plaCT

Compared with docetaxel

&lt;1%: immunotherapy

1-49%: immunotherapy

Compared with plaCT

&lt;1%: nivolumab\_ipilimumab

&lt;1%: plaCT\_immunotherapy

&lt;1%: plaCT\_nivolumab\_ipilimumab

 $\geq 50\%$ : plaCT\_immunotherapy $\geq 50\%$ : plaCT\_nivolumab\_ipilimumab

1-49%: plaCT\_immunotherapy

1-49%: plaCT\_nivolumab\_ipilimumab

